ArticleCardiovascular diabetology2023

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.

Dorte Vistisen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.